Neuren's Royalties From Daybue Sales Beat Bull's Forecast -- Market Talk

Dow Jones

03/04

2308 ET - Royalty revenue flowing to Neuren Pharmaceuticals from U.S. sales of the Daybue treatment for Rett Syndrome last year beat Macquarie's expectations. Acadia Pharmaceuticals, Neuren's partner, said U.S. net sales of Daybue totaled US$391 million in 2025. That was above the US$350 million of sales achieved in 2024. Macquarie says the sales outcome translates to A$65.0 million in royalties for Neuren, up 15% on year. This is 1.5% higher than its forecast of A$64.0 million. "Royalty revenue ahead of expectations, driven by growth in new patient prescriptions," Macquarie says. "Neuren's strong cash position enables pipeline acceleration, potentially providing significant long-term upside." It has an outperform call on Neuren. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

March 03, 2026 18:08 ET (23:08 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2616137072"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616137072\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616137072?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 07:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616137072","market":"sh","top_or_hot":-1,"title":"Neuren's Royalties From Daybue Sales Beat Bull's Forecast -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2308 ET - Royalty revenue flowing to <a href=\"https://laohu8.com/S/NEU.AU\">Neuren Pharmaceuticals</a> from U.S. sales of the Daybue treatment for Rett Syndrome last year beat <a href=\"https://laohu8.com/S/MQG.AU\">Macquarie</a>'s expectations. Acadia Pharmaceuticals, Neuren's partner, said U.S. net sales of Daybue totaled US$391 million in 2025. That was above the US$350 million of sales achieved in 2024. Macquarie says the sales outcome translates to A$65.0 million in royalties for Neuren, up 15% on year. This is 1.5% higher than its forecast of A$64.0 million. \"Royalty revenue ahead of expectations, driven by growth in new patient prescriptions,\" Macquarie says. \"Neuren's strong cash position enables pipeline acceleration, potentially providing significant long-term upside.\" It has an outperform call on Neuren. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 03, 2026 18:08 ET (23:08 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neuren's Royalties From Daybue Sales Beat Bull's Forecast -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuren's Royalties From Daybue Sales Beat Bull's Forecast -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-04 07:08</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2308 ET - Royalty revenue flowing to <a href=\"https://laohu8.com/S/NEU.AU\">Neuren Pharmaceuticals</a> from U.S. sales of the Daybue treatment for Rett Syndrome last year beat <a href=\"https://laohu8.com/S/MQG.AU\">Macquarie</a>'s expectations. Acadia Pharmaceuticals, Neuren's partner, said U.S. net sales of Daybue totaled US$391 million in 2025. That was above the US$350 million of sales achieved in 2024. Macquarie says the sales outcome translates to A$65.0 million in royalties for Neuren, up 15% on year. This is 1.5% higher than its forecast of A$64.0 million. \"Royalty revenue ahead of expectations, driven by growth in new patient prescriptions,\" Macquarie says. \"Neuren's strong cash position enables pipeline acceleration, potentially providing significant long-term upside.\" It has an outperform call on Neuren. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 03, 2026 18:08 ET (23:08 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2616137072","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616137072","pubTimestamp":1772579280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2308 ET - Royalty revenue flowing to Neuren Pharmaceuticals from U.S. sales of the Daybue treatment for Rett Syndrome last year beat Macquarie's expectations. Acadia Pharmaceuticals, Neuren's partner, said U.S. net sales of Daybue totaled US$391 million in 2025. That was above the US$350 million of sales achieved in 2024. Macquarie says the sales outcome translates to A$65.0 million in royalties for Neuren, up 15% on year. This is 1.5% higher than its forecast of A$64.0 million. \"Royalty revenue ahead of expectations, driven by growth in new patient prescriptions,\" Macquarie says. \"Neuren's strong cash position enables pipeline acceleration, potentially providing significant long-term upside.\" It has an outperform call on Neuren. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","NEU.AU":"NEUREN PHARMACEUTICALS LTD","BK7508":"医药生物股"},"translate_title":"Neuren从Daybue销售中获得的特许权使用费超出了公牛的预期——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEU.AU":0.9},"content_text":"2308 ET - Royalty revenue flowing to Neuren Pharmaceuticals from U.S. sales of the Daybue treatment for Rett Syndrome last year beat Macquarie's expectations. Acadia Pharmaceuticals, Neuren's partner, said U.S. net sales of Daybue totaled US$391 million in 2025. That was above the US$350 million of sales achieved in 2024. Macquarie says the sales outcome translates to A$65.0 million in royalties for Neuren, up 15% on year. This is 1.5% higher than its forecast of A$64.0 million. \"Royalty revenue ahead of expectations, driven by growth in new patient prescriptions,\" Macquarie says. \"Neuren's strong cash position enables pipeline acceleration, potentially providing significant long-term upside.\" It has an outperform call on Neuren. (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 03, 2026 18:08 ET (23:08 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}